<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02822495</url>
  </required_header>
  <id_info>
    <org_study_id>EBV-CTL-201</org_study_id>
    <nct_id>NCT02822495</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol for Tabelecleucel in Subjects With EBV-Associated Viremia or Malignancies</brief_title>
  <official_title>Multicenter Expanded Access Protocol of Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atara Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atara Biotherapeutics</source>
  <brief_summary>
    <textblock>
      The primary objective of this protocol is to provide access to tabelecleucel to patients with
      Epstein-Barr virus-positive post-transplant lymphoproliferative disorder (EBV+ PTLD), EBV+
      primary immunodeficiency lymphoproliferative disease (PID LPD), EBV+ acquired
      immunodeficiency (AID) LPD, and EBV viremia for whom there are no other approved therapeutic
      options, and who are not eligible to enroll in clinical studies designed to support the
      development and registration of tabelecleucel.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Epstein-Barr Virus-Associated Lymphoproliferative Disorder</condition>
  <condition>Epstein-Barr Virus Lymphoma</condition>
  <condition>Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder</condition>
  <condition>Epstein-Barr Virus-Associated Viremia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tabelecleucel</intervention_name>
    <description>Tabelecleucel is an allogeneic cellular immunotherapy for the treatment of EBV+ malignancies and diseases.</description>
    <other_name>tab-cel™</other_name>
    <other_name>ATA129</other_name>
    <other_name>EBV-CTL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Any of the following diagnoses of EBV+ disease:

               1. EBV+ PTLD following allogeneic hematopoietic cell transplant (HCT) or solid organ
                  transplant (SOT) and who cannot be treated under protocols designed to support
                  drug development or registration

               2. Persistent EBV viremia as evidenced by 2 serial serum EBV deoxyribonucleic acid
                  (DNA) assays showing detectable EBV viremia at least 4 weeks apart, and known or
                  suspected immunodeficiency, or EBV viremia with a history of prior EBV+
                  malignancy

               3. EBV+ LPD that has developed in the setting of an AID

               4. EBV+ LPD that has developed in the setting of a known or suspected PID

          2. Evidence of EBV positivity as follows:

               1. Biopsy showing EBV+ disease, OR

               2. A combination of circulating EBV DNA AND radiographic appearance consistent with
                  an EBV+ malignancy, if biopsy is not clinically feasible, OR

               3. For EBV viremia only, fulfillment of inclusion criteria 1b

          3. Relapsed or refractory disease, which is defined as:

               1. In patients with PTLD following HCT: relapsed after or refractory to reduction of
                  immunosuppression and an anti-CD20 monoclonal antibody (unless investigator
                  determines tumor to be CD20-) as a single agent or in combination with
                  chemotherapy. Patients with CD20- disease must have failed chemotherapy alone.

               2. In patients with PTLD following SOT: relapse after or refractory to reduction of
                  immunosuppression, an anti-CD20 monoclonal antibody (unless investigator
                  determines tumor to be CD20-) plus anthracycline based chemotherapy. Patients
                  with CD20- disease must have failed chemotherapy alone.

               3. In patients with EBV viremia: Viremia that persists or recurs despite therapy
                  with an anti-CD20 monoclonal antibody

               4. In patients with PID LPD: relapsed after or refractory to an anti-CD20 monoclonal
                  antibody (unless investigator determines tumor to be CD20-) as a single agent or
                  in combination with a chemotherapy

               5. In patients with AID LPD: have failed at least two prior lines of therapy, one of
                  which is an anti-CD20 monoclonal antibody (unless investigator determines tumor
                  to be CD20-) plus anthracycline based chemotherapy (Note: Remission consolidation
                  with an autologous or allogeneic stem cell transplant will not be considered as a
                  separate line of therapy).

          4. Not eligible for any other studies supporting development of tabelecleucel

          5. For patients with PTLD in the allogeneic HCT setting, the underlying disease for which
             allogeneic HCT was performed is in morphologic remission

          6. Adequate organ function per the following:

               1. Absolute neutrophil count ≥ 500/μL, with or without cytokine support

               2. Platelet count ≥ 20,000/μL, with or without transfusion support

          7. Patient or patient's representative is willing and able to provide written informed
             consent

        Exclusion Criteria:

          1. Burkitt's lymphoma, classical Hodgkin's lymphoma, plasmablastic lymphoma, or any
             T-cell lymphoma

          2. Any investigational therapy received within 4 weeks prior to Cycle 1 Day 1, except for
             therapy that is outside of 5 half-lives from the most recent dose to Cycle 1 Day 1

          3. Ongoing need for methotrexate or extracorporeal photopheresis; steroid doses &gt; 1
             mg/kg/day, as prednisone equivalent

          4. Need for vasopressor or ventilatory support, unless deemed to be caused by the
             EBV-driven process that tabelecleucel is intended to treat

          5. Antithymocyte globulin, alemtuzumab, or similar anti-T-cell antibody therapy, or
             T-cell immunotherapy (donor lymphocyte infusion, other CTLs) ≤ 4 weeks prior to Cycle
             1 Day 1

          6. Pregnancy

          7. Female of childbearing potential or male with a female partner of childbearing
             potential unwilling to use a highly effective method of contraception, except when, in
             the opinion of the treating physician in consultation with the medical monitor, the
             risk/benefit of tabelecleucel therapy favors proceeding

          8. Inability to comply with protocol procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Willis Navarro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Atara Biotherapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Atara Biotherapeutics, Inc.</last_name>
    <phone>(805) 603-4856</phone>
    <email>clinicaltrials@atarabio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Wen-Kai Weng, MD</last_name>
      <phone>650-723-0822</phone>
      <email>wkweng@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Pamela Valentino, MD</last_name>
      <phone>203-785-4649</phone>
      <email>pamela.valentino@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>John Fort, MD</last_name>
      <phone>352-273-9120</phone>
      <email>john.fort@ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Amer Beitinjaneh, MD</last_name>
      <phone>305-243-6626</phone>
      <email>abeitinjaneh@miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jonathon Cohen, MD</last_name>
      <phone>404-778-3942</phone>
      <email>jonathon.cohen@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sonali Chaudhury, MD</last_name>
      <phone>312-227-4090</phone>
      <email>schaudhury@luriechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Patrick Stiff, MD</last_name>
      <phone>708-327-3148</phone>
      <email>pstiff@lumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sarah Nikiforow, MD, PhD</last_name>
      <phone>617-632-6640</phone>
      <email>snikiforow@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Aleksandr Lazaryan, MD</last_name>
      <phone>612-624-0123</phone>
      <email>alazarya@umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University, School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Armin Ghobadi, MD</last_name>
      <phone>314-454-2743</phone>
      <email>aghobadi@dom.wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Murali Janakiram, MD</last_name>
      <phone>718-920-4826</phone>
      <email>mjanakir@montefiore.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David Loeb, MD, PhD</last_name>
      <phone>718-741-2342</phone>
      <email>dloeb@montefiore.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Koen van Besien, MD</last_name>
      <phone>212-746-2048</phone>
      <email>kov9001@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ran Reshef, MD</last_name>
      <phone>212-342-0530</phone>
      <email>rr3036@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Susan Prockop, MD</last_name>
      <phone>212-639-6715</phone>
      <email>prockops@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Marcie Riches, MD</last_name>
      <phone>919-966-7746</phone>
      <email>marcie_riches@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rolla Abu-Arja, MD</last_name>
      <phone>614-722-3250</phone>
      <email>rolla.abu-arja@nationwidechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University - Arthur G. James Cancer Center Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Robert Baiocchi, MD</last_name>
      <phone>614-293-3196</phone>
      <email>robert.baiocchi@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Eneida Nemecek, MD</last_name>
      <phone>503-494-0829</phone>
      <email>nemeceke@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Donald Tsai, MD</last_name>
      <phone>215-614-0037</phone>
      <email>donald.tsai@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nancy J Bunin, MD</last_name>
      <phone>215-590-2255</phone>
      <email>buninn@email.chop.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ashok Srinivasan, MD</last_name>
      <phone>901-595-4720</phone>
      <email>ashok.srinivasan@stjude.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ann E Dahlberg, MD</last_name>
      <phone>206-667-1959</phone>
      <email>adahlberg@fredhutch.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>July 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2016</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoproliferative Disorders</keyword>
  <keyword>Epstein-Barr Virus</keyword>
  <keyword>Epstein-Barr Viremia</keyword>
  <keyword>Post Transplant Lymphoproliferative Disorder</keyword>
  <keyword>EBV-PTLD</keyword>
  <keyword>Solid Organ Transplant</keyword>
  <keyword>Hematopoietic Cell Transplant</keyword>
  <keyword>primary immunodeficiency</keyword>
  <keyword>acquired immunodeficiency</keyword>
  <keyword>Epstein-Barr Virus Lymphoma</keyword>
  <keyword>HIV/AIDS lymphoma</keyword>
  <keyword>Rheumatoid arthritis AND lymphoma</keyword>
  <keyword>Allogeneic, off-the-shelf T-cell immunotherapy</keyword>
  <keyword>TNF-alpha inhibitors AND lymphoma</keyword>
  <keyword>Inflammatory bowel disease AND lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Viremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

